Food for Thought: The Case for Two FDAs
This article was originally published in RPM Report
Executive Summary
Is it time to rethink the combination of food regulation with drugs and devices? One powerful member of Congress thinks so. The separation could be good for FDA, and maybe for biopharma companies too. But it is also a distraction at a bad time for the agency.
You may also be interested in...
Using REMS to Ram Drugs through FDA Faster
FDA's use of Risk Evaluation & Mitigation Strategies will require NDA and BLA sponsors to provide more rigorous definitions of patient populations. Former FDA Commissioner Kessler thinks that may break the logjam on approvals.
Nickel and Diming FDA
Everyone agrees FDA needs more money to do its job. Its not getting it. Does that mean the drug safety law will just end up making a bad situation worse?
The Power of the Purse: FDA Seeks More Money, Not More Authority
Congress can't wait to shower FDA with more regulatory authority, especially in the area of drug safety. But unless Capitol Hill can puts its money where its mouth is, expanding FDA's mission will only send the agency deeper into a fiscal crisis -- and leave industry worse off as a result. An underfunded agency leaves officials scrambling to complete day-to-day activities -- and less time to on activities to further drug development, like nanotechnology and the Critical Path initiative.